Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics

– Proceeds include $170 million in upfront cash and up to $10 million earn-out over two years – GERMANTOWN, Md., Aug. 22, 2022 /PRNewswire/ — Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.